logo-loader

PROLOR Biotech reports positive results from obesity drug animal study

Published: 17:33 06 Jun 2011 BST

no_picture_pai

PROLOR Biotech (AMEX:PBTH) announced Monday that its longer-acting anti-obesity drug, oxyntomodulin (OXY-RPEG), showed greater weight loss and reduced food intake in an animal study.

Oxyntomodulin is a naturally-occurring peptide hormone released by the digestive system. It indicates to the body the feeling of being "full" so as to reduce food intake, and increase energy expenditure following a meal. However, the hormone has a very short half-life, meaning that it doesn't take long for the substance to be consumed by half in the decaying process.

But PROLOR developed the longer-lasting OXY-PREG, which is a combination of the naturally occurring oxyntomodulin, with the company's Reversible PEGylation technology, designed to increase the half-life of therapeutic peptides and small molecules, enabling the dose to last longer.

The animal study examined the effect of OXY-RPEG injected once or twice weekly, compared to a twice daily injection of the naturally-occurring oxyntomodulin, when looking at weight loss and a reduction in food intake.

The trial showed that subjects injected with OXY-RPEG once or twice per week had significantly higher weight loss, reduced food intake and a longer duration of weight loss activity, compared to the twice daily oxyntomodulin.

The company said that OXY-RPEG also demonstrated greater potency, with the total dose administered over the week containing approximately 15% of the cumulative dose of oxyntomodulin injected during the same period.

"We believe that oxyntomodulin's natural role as an appetite suppressant and its anticipated favorable safety profile make it a promising potential weight loss therapy for the millions of obese patients who currently lack safe and effective treatment options," said CEO Dr. Abraham Havron.

The Nes Ziona, Israel-based company, whose stock on the AMEX was up 2.99% on Monday morning, trading at $5.16 per share, said it will use the positive results to initiate additional drugs using its technology.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

3 hours, 8 minutes ago